Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease

Thomas J. Montine, Joseph Quinn, Dejan Milatovic, Lisa Silbert, Theresa Dang, Stephanie Sanchez, Erin Terry, L. Jackson Roberts, Jeffrey Kaye, Jason D. Morrow

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Quantitative biomarkers of oxidative damage, such as the F2-isoprostanes (IsoPs) and F4-neuroprostanes (F4-NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F2-IsoPs and F4-NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F2-IsoPs and F4-NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F2-IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F2-IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F2-IsoPs and F4-NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F2-IsoPs and F4-NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalAnnals of Neurology
Volume52
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Neuroprostanes
F2-Isoprostanes
Alzheimer Disease
Urine
Central Nervous System
Cerebrospinal Fluid
Biomarkers
Kainic Acid
Body Fluids
Clinical Trials

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. / Montine, Thomas J.; Quinn, Joseph; Milatovic, Dejan; Silbert, Lisa; Dang, Theresa; Sanchez, Stephanie; Terry, Erin; Roberts, L. Jackson; Kaye, Jeffrey; Morrow, Jason D.

In: Annals of Neurology, Vol. 52, No. 2, 2002, p. 175-179.

Research output: Contribution to journalArticle

Montine, TJ, Quinn, J, Milatovic, D, Silbert, L, Dang, T, Sanchez, S, Terry, E, Roberts, LJ, Kaye, J & Morrow, JD 2002, 'Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease', Annals of Neurology, vol. 52, no. 2, pp. 175-179. https://doi.org/10.1002/ana.10272
Montine, Thomas J. ; Quinn, Joseph ; Milatovic, Dejan ; Silbert, Lisa ; Dang, Theresa ; Sanchez, Stephanie ; Terry, Erin ; Roberts, L. Jackson ; Kaye, Jeffrey ; Morrow, Jason D. / Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. In: Annals of Neurology. 2002 ; Vol. 52, No. 2. pp. 175-179.
@article{d08714aff4d34b2797610c1bbf3960c6,
title = "Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease",
abstract = "Quantitative biomarkers of oxidative damage, such as the F2-isoprostanes (IsoPs) and F4-neuroprostanes (F4-NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F2-IsoPs and F4-NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F2-IsoPs and F4-NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F2-IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F2-IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F2-IsoPs and F4-NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F2-IsoPs and F4-NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease.",
author = "Montine, {Thomas J.} and Joseph Quinn and Dejan Milatovic and Lisa Silbert and Theresa Dang and Stephanie Sanchez and Erin Terry and Roberts, {L. Jackson} and Jeffrey Kaye and Morrow, {Jason D.}",
year = "2002",
doi = "10.1002/ana.10272",
language = "English (US)",
volume = "52",
pages = "175--179",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease

AU - Montine, Thomas J.

AU - Quinn, Joseph

AU - Milatovic, Dejan

AU - Silbert, Lisa

AU - Dang, Theresa

AU - Sanchez, Stephanie

AU - Terry, Erin

AU - Roberts, L. Jackson

AU - Kaye, Jeffrey

AU - Morrow, Jason D.

PY - 2002

Y1 - 2002

N2 - Quantitative biomarkers of oxidative damage, such as the F2-isoprostanes (IsoPs) and F4-neuroprostanes (F4-NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F2-IsoPs and F4-NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F2-IsoPs and F4-NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F2-IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F2-IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F2-IsoPs and F4-NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F2-IsoPs and F4-NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease.

AB - Quantitative biomarkers of oxidative damage, such as the F2-isoprostanes (IsoPs) and F4-neuroprostanes (F4-NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F2-IsoPs and F4-NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F2-IsoPs and F4-NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F2-IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F2-IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F2-IsoPs and F4-NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F2-IsoPs and F4-NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0035984342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035984342&partnerID=8YFLogxK

U2 - 10.1002/ana.10272

DO - 10.1002/ana.10272

M3 - Article

C2 - 12210787

AN - SCOPUS:0035984342

VL - 52

SP - 175

EP - 179

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -